ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 2

Long-Term Follow-Up from CheckMate 214 in Advanced RCC

, , , ,

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    x